Five Prime Therapeutics Inc – NASDAQ:FPRX
Five Prime Therapeutics stock price today
Five Prime Therapeutics stock price monthly change
Five Prime Therapeutics stock price quarterly change
Five Prime Therapeutics stock price yearly change
Five Prime Therapeutics key metrics
Market Cap | 52.20M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -2.38 |
Revenue | 13.17M |
EBITDA | -85.05M |
Income | -84.32M |
Revenue Q/Q | -122.05% |
Revenue Y/Y | -11.40% |
Profit margin | -639.91% |
Oper. margin | -704.74% |
Gross margin | 15.54% |
EBIT margin | -704.74% |
EBITDA margin | -645.45% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeFive Prime Therapeutics stock price history
Five Prime Therapeutics stock forecast
Five Prime Therapeutics financial statements
| Mar 2020 | 8.41M | -20.11M | -239.08% |
|---|---|---|---|
| Jun 2020 | 3.42M | -16.93M | -494.66% |
| Sep 2020 | 2.04M | -26.42M | -1290.19% |
| Dec 2020 | -708K | -20.85M | 2945.2% |
| 2020-05-07 | -0.67 | -0.57 |
|---|---|---|
| 2020-08-06 | -0.69 | -0.48 |
| 2020-11-03 | -0.6 | -0.74 |
| 2021-03-22 | -0.52 | -0.51 |
| Mar 2020 | 202971000 | 68.42M | 33.71% |
|---|---|---|---|
| Jun 2020 | 185345000 | 65.40M | 35.29% |
| Sep 2020 | 160381000 | 65.15M | 40.62% |
| Dec 2020 | 331650000 | 66.55M | 20.07% |
| Mar 2020 | -15.07M | 27.24M | -277K |
|---|---|---|---|
| Jun 2020 | -20.99M | 11.81M | 196K |
| Sep 2020 | -15.32M | -7.06M | -307K |
| Dec 2020 | -13.26M | -142.62M | 189.29M |
Five Prime Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Dec 2019 | 650020 | 79980 |
| May 2020 | 587174 | 0 |
| Sep 2020 | 32 | 0 |
| Oct 2020 | 690482 | 0 |
| Nov 2020 | 893124 | 22232979 |
| Patent |
|---|
Grant Utility: FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment Filling date: 22 Nov 2016 Issue date: 20 Sep 2022 |
Grant Filling date: 12 Sep 2018 Issue date: 23 Aug 2022 |
Grant Utility: Antibodies binding to ILT4 Filling date: 9 Jul 2019 Issue date: 2 Aug 2022 |
Application Filling date: 1 May 2020 Issue date: 21 Jul 2022 |
Application Filling date: 17 Dec 2021 Issue date: 2 Jun 2022 |
Application Filling date: 28 Oct 2021 Issue date: 19 May 2022 |
Grant Filling date: 23 Aug 2018 Issue date: 19 Apr 2022 |
Application Filling date: 10 Jul 2019 Issue date: 10 Mar 2022 |
Application Filling date: 2 Jul 2021 Issue date: 10 Feb 2022 |
Grant Filling date: 6 Nov 2018 Issue date: 1 Feb 2022 |
| Quarter | Transcript |
|---|---|
| Q3 2020 3 Nov 2020 | Q3 2020 Earnings Call Transcript |
| Q2 2020 9 Aug 2020 | Q2 2020 Earnings Call Transcript |
| Q1 2020 9 May 2020 | Q1 2020 Earnings Call Transcript |
| Q4 2019 28 Feb 2020 | Q4 2019 Earnings Call Transcript |
-
What's the price of Five Prime Therapeutics stock today?
One share of Five Prime Therapeutics stock can currently be purchased for approximately $38.
-
When is Five Prime Therapeutics's next earnings date?
Unfortunately, Five Prime Therapeutics's (FPRX) next earnings date is currently unknown.
-
Does Five Prime Therapeutics pay dividends?
No, Five Prime Therapeutics does not pay dividends.
-
How much money does Five Prime Therapeutics make?
Five Prime Therapeutics has a market capitalization of 52.20M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 11.4% to 13.18M US dollars. Five Prime Therapeutics made a loss 84.33M US dollars in net income (profit) last year or -$0.51 on an earnings per share basis.
-
What is Five Prime Therapeutics's stock symbol?
Five Prime Therapeutics Inc is traded on the NASDAQ under the ticker symbol "FPRX".
-
What is Five Prime Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Five Prime Therapeutics?
Shares of Five Prime Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Five Prime Therapeutics have?
Five Prime Therapeutics Inc employs 87 workers.
-
When Five Prime Therapeutics went public?
Five Prime Therapeutics Inc is publicly traded company for more then 12 years since IPO on 18 Sep 2013.
-
What is Five Prime Therapeutics's official website?
The official website for Five Prime Therapeutics is fiveprime.com.
-
Where are Five Prime Therapeutics's headquarters?
Five Prime Therapeutics is headquartered at 111 Oyster Point Blvd, South San Francisco, CALIFORNIA.
-
How can i contact Five Prime Therapeutics?
Five Prime Therapeutics's mailing address is 111 Oyster Point Blvd, South San Francisco, CALIFORNIA and company can be reached via phone at +1 415 365 5600.
Five Prime Therapeutics company profile:
Five Prime Therapeutics Inc
fiveprime.comNASDAQ
87
Biotechnology
Healthcare
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
South San Francisco, CALIFORNIA 94080
CIK: 0001175505
ISIN: US33830X1046
CUSIP: 33830X104
